undamentalytics Newsletter
Sign in

Fortress Biotech, Inc. key statistics and ratios

In fiscal 2025, Fortress Biotech, Inc. had return on equity of 18.8% and a net margin of 10.8%. Each ratio below is calculated from the figures on its income statement, balance sheet and cash flow pages.

Financial ratios

US$ thousands unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2013Dec 20132014Dec 20142015Dec 20152016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Net margin——<−999%−334.3%−35.7%−313.0%−109.1%−102.0%−94.1%−114.3%−71.7%−79.8%10.8%163.3%
Return on equity−45.7%−26.9%−76.0%−115.6%−146.9%——−73.5%−61.9%−115.1%−188.7%—18.8%104.5%
Return on assets−36.9%−21.5%−46.6%−38.1%−32.1%−43.5%−21.8%−16.6%−17.7%−25.1%−26.3%−29.5%4.1%44.5%
Effective tax rate—————————————3.2%
R&D as % of revenue——>999%213.2%25.8%325.1%222.0%140.6%187.3%178.1%125.5%98.2%18.8%1.7%
SG&A as % of revenue—————198.5%151.8%134.1%126.2%150.1%107.7%152.1%152.4%100.6%
Dividends ÷ net income————————————9.7%—

Returns use average equity or assets over the year. Return on equity is left blank when equity is negative or so small that the ratio says nothing (above ±200%); interest cover is left blank above 200 times. Price-based ratios such as P/E are on the valuation page.

Financial health

6 of 7 checks passed · June 30, 2026
What it owns · $317m
Short-term assets $246mLonger-term assets $71m
What it owes, and who funded it · $275m
Short-term liabilities $62mLonger-term liabilities $49mShareholders' equity $164m
  • Short-term assets cover short-term liabilities $246m of assets due within a year against $62m of liabilities due within a year.
  • Short-term assets cover long-term liabilities $246m short-term assets against $49m of longer-dated liabilities.
  • More cash than debt $197m of cash against $35m of debt.
  • Debt below 40% of shareholders' equity Debt is 21% of equity.
  • Debt burden no higher than five years ago Debt to equity moved from 40% to 21% over five years.
  • A year's operating cash flow covers at least 20% of debt $126m of operating cash flow against $35m of debt.
  • Operating profit covers interest at least five times over Operating income of −$29m against $10m of interest.

From Fortress Biotech, Inc.'s latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Moat

20 /100

Weak moat

How hard Fortress Biotech's competitive advantage looks for rivals to wear away, judged from 10 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.

  • Returns on capital 0 / 20

    Cash operating profit has been a median -14.2% of total assets over 8 years.

  • Pricing power 14 / 20

    Gross margin has been a median 66.9%, moving by 7.6 percentage points (standard deviation) across 8 years.

  • Durability 10 / 20

    Operating margin has been a median -202.5%; its worst year was -425.9%.

  • Cash conversion 1 / 20

    Free cash flow was positive in 1 of 10 years, at a median -160.5% of revenue.

  • Discipline 0 / 20

    The diluted share count rose 997.2% over five years; stock-based pay has been a median 27.1% of revenue.

AI disruption exposure: Medium. In this industry, AI could change how the product is made or sold, without replacing the core asset. The score above includes a 5-point deduction for that exposure (25 before it).

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Compare with peers

Head to head: FBIO vs RXRXCYTK vs FBIOABCL vs FBIO

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Fortress Biotech, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Fortress Biotech, Inc.